BioDivide Ltd, a Stem Cell Company, Announces New Website Launch
The new website offers visitors rich insights into the Company’s lead stem cell product, StemPlan, and applied expertise of the therapeutic and biotechnology applications of stem cells. The website also provides a complete overview of the Company’s GMP facilities and service offerings engineered to harness the power of stem cells and regenerative medicine.
Melksham, United Kingdom, April 18, 2018 --(PR.com)-- The new website offers visitors rich insights into the Company’s lead stem cell product, StemPlan, and applied expertise of the therapeutic and biotechnology applications of stem cells.
BioDivide Limited (“BioDivide” or the “Company), a world leader in stem cell and regenerative medicines, products, tools, technologies and services, announced today the launch of its new website. The Company’s unique and innovative stem cell product, StemPlan, is a feature in the new website. StemPlan is a stem cell therapy approved by the UK Veterinary Medicine’s Directorate that uses a non-invasive proprietary and innovative method of collecting stem cells. Not offered by any other company, StemPlan uniquely provides horse owners with readily available stem cell therapy when they need it most.
The new website offers a comprehensive understanding of stem cell therapy and how regenerative medicine leads to repair of injured or diseased tissue to restore normal function. The website also provides a complete overview of the Company’s GMP facilities and service offerings engineered to harness the power of stem cells and regenerative medicine. BioDivide’s commitment to quality and biologicals manufacturing capabilities are emphasised in the new site.
The new website goes live today and is located at http://www.biodivide.com.
“We are excited about our new website launch and the comprehensive information it provides about BioDivide’s exclusive products and services,” said Dr Erik Miljan, BioDivide’s founder and Chief Executive Officer. “We believe that this new site provides valuable information about stem cell therapy to the public and our customers.”
“Not all stem cells are the same. Manufacturing a top quality stem cell product requires understanding the biology and process that will give you different characteristics, whether consistency, purity or potency,” added Dr Miljan.
BioDivide provides the highest quality stem cell supportive therapy products and services. The Company’s quality systems incorporate needle-to-needle traceability for the complete supply chain. Visitors are encouraged to explore the new website to learn more about stem cells and regenerative medicine.
About BioDivide
BioDivide is a leader in regenerative medicines, tools, technologies and services. Based in the Southwest UK, the Company combines extensive knowledge and expertise of the therapeutic applications of stem cells. BioDivide offers biomedical research capabilities to undertake stem cell research and brings regenerative medicine to patients quickly and efficiently. The Company’s lead product, StemPlan, is a stem cell therapy approved by the UK Veterinary Medicine’s Directorate that uses a non-invasive method of collecting stem cells for the treatment of equine patients. StemPlan provides assurance & peace of mind to horse owners.
BioDivide is a proud member of the United Kingdom’s Biotechnology Industry Association (BIA) and the Oxford Biotechnology Network (OBN).
BioDivide Limited (“BioDivide” or the “Company), a world leader in stem cell and regenerative medicines, products, tools, technologies and services, announced today the launch of its new website. The Company’s unique and innovative stem cell product, StemPlan, is a feature in the new website. StemPlan is a stem cell therapy approved by the UK Veterinary Medicine’s Directorate that uses a non-invasive proprietary and innovative method of collecting stem cells. Not offered by any other company, StemPlan uniquely provides horse owners with readily available stem cell therapy when they need it most.
The new website offers a comprehensive understanding of stem cell therapy and how regenerative medicine leads to repair of injured or diseased tissue to restore normal function. The website also provides a complete overview of the Company’s GMP facilities and service offerings engineered to harness the power of stem cells and regenerative medicine. BioDivide’s commitment to quality and biologicals manufacturing capabilities are emphasised in the new site.
The new website goes live today and is located at http://www.biodivide.com.
“We are excited about our new website launch and the comprehensive information it provides about BioDivide’s exclusive products and services,” said Dr Erik Miljan, BioDivide’s founder and Chief Executive Officer. “We believe that this new site provides valuable information about stem cell therapy to the public and our customers.”
“Not all stem cells are the same. Manufacturing a top quality stem cell product requires understanding the biology and process that will give you different characteristics, whether consistency, purity or potency,” added Dr Miljan.
BioDivide provides the highest quality stem cell supportive therapy products and services. The Company’s quality systems incorporate needle-to-needle traceability for the complete supply chain. Visitors are encouraged to explore the new website to learn more about stem cells and regenerative medicine.
About BioDivide
BioDivide is a leader in regenerative medicines, tools, technologies and services. Based in the Southwest UK, the Company combines extensive knowledge and expertise of the therapeutic applications of stem cells. BioDivide offers biomedical research capabilities to undertake stem cell research and brings regenerative medicine to patients quickly and efficiently. The Company’s lead product, StemPlan, is a stem cell therapy approved by the UK Veterinary Medicine’s Directorate that uses a non-invasive method of collecting stem cells for the treatment of equine patients. StemPlan provides assurance & peace of mind to horse owners.
BioDivide is a proud member of the United Kingdom’s Biotechnology Industry Association (BIA) and the Oxford Biotechnology Network (OBN).
Contact
BioDivide Limited
Dr. Erik Miljan
+44 (0) 1225 790 326
www.biodivide.com
Dr. Erik Miljan
+44 (0) 1225 790 326
www.biodivide.com
Contact
Categories